Could a Once-Daily pill make life easier for kidney transplant patients?
NCT ID NCT03979365
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 261 kidney transplant patients to see if taking a once-daily anti-rejection drug (Envarsus XR) leads to fewer side effects and better medication adherence compared to the standard twice-daily drug. Patients reported symptoms like trembling, muscle cramps, and gum swelling. The goal was to improve quality of life without changing the need for lifelong anti-rejection medication.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT RECIPIENTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic Florida
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common diabetes drug protect transplanted kidneys?
- Could a diabetes drug duo protect transplanted kidneys?
- Gene study seeks clues to Longer-Lasting kidney transplants
- Laser gum treatment shows promise for kidney transplant patients
- Could vitamins a and B3 shield kidney transplant patients from skin cancer?
- Personalized antibiotic strategy aims to prevent deadly infections after kidney transplant